The Value of Ipsilateral Breast Tumor Recurrence as a Quality Indicator: Hospital Variation in the Netherlands
- 236 Downloads
All Dutch hospitals are obliged to report their 5-year ipsilateral breast tumor recurrence (IBTR) rate after breast cancer surgery. Experts decided that these rates should not exceed 5 %. This study determined the value of IBTR as an indicator to compare quality of care between hospitals.
All patients with breast cancer (pT1–3, any N, M0) who underwent surgery in 1 of 92 Dutch hospitals from 2003 to 2006 were identified in the Netherlands Cancer Registry. Data of recurrence was retrieved from hospital records. Five-year IBTR rates for breast-conserving surgery (BCS) and mastectomy were calculated by using the Kaplan–Meier method. Hospital variation was presented in funnel plots. Multivariate analysis was used to assess hospital characteristics associated with IBTR rates.
A total of 40,892 breast cancer patients were included. The overall 5-year IBTR rate was 2.85 % (95 % confidence interval 2.68–3.03) and was significantly lower for BCS than for mastectomy (2.38 vs. 3.45 %, p < 0.001). IBTR rates decreased over time in both groups. Rates varied between 0.77 and 5.70 % between hospitals. When random variation is taken into account, only extremely high IBTR rates can be detected as deviant from the target value of 5 %. Adjusting for tumor and patient characteristics, analyses showed that a higher volume of mastectomies is associated with lower IBTR rates.
Our population-based findings show that IBTR rates in the Netherlands are low and have improved over time. The 5-year IBTR rate as an indicator for quality of care of individual hospitals is of limited value.
KeywordsBreast Cancer Hospital Volume Ipsilateral Breast Tumor Recurrence Dutch Hospital Final Surgery
Conflict of interest
The authors declare that they have no conflict of interest.
- 6.Rutgers EJ, Wittenberg J, Kuijpers AC. Kwaliteit van zorg rond mammacarcinoom in de etalage. In: Utrecht: CBO, Orde van Medisch Specialisten; 2006.Google Scholar
- 8.van der Heiden-van der Loo M, Ho VK, Damhuis RA, Siesling S, Menke MB, Peeters PH, Rutgers EJ: Percentage of local recurrence following treatment for breast cancer is not a suitable performance indicator. Nederlands Tijdschrift Geneeskunde. 2010;154:A1984.Google Scholar
- 10.Sobin LH, Wittekind C. TNM Classification of malignant tumours. International Union against cancer (UICC), vol. 6. New York: Wiley-Liss; 2002.Google Scholar
- 11.Moossdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM, Giuliano AE, Haffty BG, Hickey BE, Hudis CA, et al. Maastricht delphi consensus on event definitions for classification of recurrence in breast cancer research. J Natl Cancer Inst. 2014;106(12):dju288.PubMedPubMedCentralCrossRefGoogle Scholar
- 13.Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.PubMedCrossRefGoogle Scholar
- 14.Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRefGoogle Scholar
- 16.Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, Silver B, Hetelekidis S, Abner A, Harris JR, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol. 2000;18(8):1668–75.PubMedGoogle Scholar
- 20.Tjan-Heijnen VC, Van Bommel ACM, van der Heiden-van der Loo M, Westenend PJ, De Vries B, Smorenburg CH, Jager A, Lobbes MB, Pijnappel RM, Maduro JH, et al. Multidisciplinary breast cancer care registry and quality control system in the Netherlands: The NABON breast cancer audit. In 37th Annual San Antonio Breast Cancer Symposium. San Antonio;2014.Google Scholar
- 21.Van Bommel ACM, Vrancken Peeters MJ, van der Heiden-van der Loo M, Van Dalen T, Rutgers E, Wouters MW, Lobbes MB, Pijnappel RM, Mureau MA, Westenend PJ, et al. The NABON breast cancer audit; quality improvement in three years’ time. In 27th Annual San Antonio Breast Cancer Symposium. San Antonio;2014.Google Scholar